Alvotech SA
alvotech.comWhat Do They Do?
Develops and manufactures biosimilar medicines for patients worldwide, and licenses them to pharmaceutical companies for commercialization.
20-F for FY2025, filed Mar 31, 2026
Who Are Their Customers?
Pharmaceutical companies buy directly as commercial partners, then market and sell the medicines in their territories.
20-F for FY2025, filed Mar 31, 2026The Company recognizes revenue from the sale of its biosimilar product to commercial partners, identified as the customer, when control is…View ↗
A significant part of the Group’s revenue is generated from long-term out-license contracts which provide the customer with an exclusive…View ↗
We aim to improve the health and quality of life of patients around the world, broadening the availability and accessibility of biosimilars…View ↗
How Are They Changing?
Pipeline to approvals
The older report described medicines in development, while the latest report lists biosimilars for Humira, Stelara, Simponi, Eylea, and Prolia/Xgeva as approved in major markets.
20-F for FY2022, filed Mar 1, 2023 20-F for FY2025, filed Mar 31, 2026Through our rigorous product selection and development platform, we have been able to build a pipeline comprising five disclosed biosimilar…View ↗
Our biosimilar to Humira (adalimumab) has been approved in various major markets including the U.S., Canada, UK and European Economic Area.…View ↗
Our biosimilar to Stelara (ustekinumab) has been approved for marketing in various major markets including the U.S., Canada, UK, European…View ↗
Our biosimilar to Simponi (golimumab) has been approved for marketing in the UK, European Economic Area and Japan. Golimumab is a TNF…View ↗
Our biosimilar to Eylea (aflibercept) has been approved for marketing in the UK, European Economic Area and Japan. Aflibercept is a…View ↗
Our biosimilar to Prolia and Xgeva, which both contain denosumab, has been approved in the UK, European Economic Area and Japan. Denosumab…View ↗
Who Do They Compete With?
Competes with Amgen, Biocon, Celltrion, Fresenius Kabi, Pfizer, Samsung Bioepis, Sandoz, Boehringer Ingelheim, King-Friend, Intas, Formycon, Gedeon Richter, Accord, Bio-Thera, Regeneron, STADA, Sam Chun Dang, Polpharma, Mabxience, and Sciencepharma
20-F for FY2025, filed Mar 31, 2026AVT02. In addition to AbbVie’s (the originator’s) reference product, we can face competition from other approved biosimilars for Humira…View ↗
Loading...
